Drug firm Jubilant Pharmova on Friday reported a consolidated net profit of Rs 160.49 crore from continuing operations for the quarter ended June 30, 2021.
The company had posted a net profit of Rs 35.39 crore for the year-ago period, Jubilant Pharmova said in a regulatory filing.
Revenue from continuing operations stood at Rs 1,634.65 crore in the quarter under review. It was Rs 1,156.07 crore in the same period a year ago, it added.
Figures for the quarter are not comparable with previous periods since the Life Science Ingredients business was demerged with effect from February 1, 2021 pursuant to the composite scheme of arrangement during the previous year, the filing said.
"During this quarter, in addition to YoY increase, we also reported sequential improvement in the specialty pharma segment with gradual recovery across radiopharmaceuticals, radiopharmacy and allergy business," Jubilant Pharmova Chairman Shyam S Bhartia and Co-Chairman & MD Hari S Bhartia said in a statement.
With a gradual recovery in nuclear medicine procedures, the turnaround plan of radiopharmacy business is on track. CMO business continued to benefit from COVID related deals, they added.
"Contract Research and Development Services business witnessed strong YoY (year-on-year) growth in revenues led by healthy demand from customers. We have doubled our chemistry research capacity and the facility is operational now," the statement added.
Jubilant Pharmova board at its meeting held on July 23, 2021, approved the demerger of the active pharmaceutical ingredients (API) undertaking of Jubilant Generics and vesting of the same with Jubilant Pharmova on a going concern basis, the filing said.
Shares of Jubilant Pharmova settled at Rs 696.90 apiece on BSE, down 2.59 per cent from the previous close.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU